Pharmacologic approaches to heart failure. (2014)

• Record Type: Book
• Further Information: Note: Edited by Kirkwood F. Adams Jr.
• Editors: Adams, Kirkwood F
• Contents: Inhibitors of the RAASMechanisms of RAAS Blockade Benefit in Human HF; Hemodynamics; Reverse remodeling; Antiarrhythmic effects; Other effects; ACE (aldosterone) escape; Natriuretic peptides and cardiovascular physiology; Targeting Natriuretic Peptides for HF Therapy; Vasopressin in HF pathophysiology and pharmacotherapy; Summary; References; Mineralcorticoid Antagonists in Heart Failure; Key points; Introduction; Role of aldosterone in HF; MRAs in HF clinical trials; Spironolactone; Canrenone; Eplerenone; MRAs in HF with preserved ejection fraction (HFPEF). Novel approaches to MR blockade in HFNonsteroidal MRAs; Aldosterone Synthase Inhibitors; Summary; References; Current Perspectives on Hydralazine and Nitrate Therapies in Heart Failure; Key points; Introduction; Historical perspectives: the randomized controlled clinical trials of H+ISDN; Vasodilators-Heart Failure Trial I-1986; Vasodilator-Heart Failure II-1991; African-American Heart Failure Trial-2004; The H+ISDN benefit: hemodynamic effects or fundamental pathophysiology?; Who should take hydralazine? Does race matter? Does gender matter? Does age matter?; Race and H+ISDN. Gender and H+ISDNAge and H+ISDN; The role of H+ISDN outside of chronic HF; Acutely Decompensated Systolic Heart Failure; Secondary Pulmonary Hypertension in Heart Failure; Maintaining the nitroso-redox balance: is hydralazine necessary?; ACEIs + Nitrates; Other Agents + Nitrates; H+ISDN in clinical practice; Summary; References; Polypharmacy in Heart Failure; Key points; Introduction; Evidence-based combination therapy in heart failure with reduced ejection fraction; Determination of Volume Status; Addition of ACE Inhibitor or Angiotensin Receptor Blocker; Addition of BB. Addition of ARA and/or Nitrates Plus HydralazineAdditional Pharmacologic Therapies for Heart Failure with Reduced Ejection Fraction; Combination Renin-Angiotensin-Aldosterone System Blockade; Renin Inhibitors; Pharmacologic management of common comorbidities; Conditions Requiring Use of Antiplatelet and Anticoagulant Therapy; Chronic Obstructive Pulmonary Disease; Diabetes Mellitus; Renal Dysfunction; Anemia and Iron Deficiency; Depression; Arthritis and Gout; Infectious Diseases; Medications to avoid; Prescription Medications; Nonprescription Medications.
• Publisher Details: Philadelphia, Pennsylvania : Elsevier
• Publication Date: 2014
• Extent: 1 online resource
• Subjects: 616.129; Heart failure -- Chemotherapy; HEALTH & FITNESS -- Diseases -- General; MEDICAL -- Clinical Medicine; MEDICAL -- Diseases; MEDICAL -- Evidence-Based Medicine; MEDICAL -- Internal Medicine; Heart failure -- Chemotherapy; Electronic books
• Languages: English
• ISBNs: 9780323326124; 0323326129
• Related ISBNs: 9780323326117; 0323326110
• Notes: Note: Print version record.
• Access Rights: Legal Deposit; Only available on premises controlled by the deposit library and to one user at any one time; The Legal Deposit Libraries (Non-Print Works) Regulations (UK).
• Access Usage: Restricted: Printing from this resource is governed by The Legal Deposit Libraries (Non-Print Works) Regulations (UK) and UK copyright law currently in force.